Twenty-five years ago, a monograph on gastric cancer was published by the Italian Society of Surgery: that book is recognized as a milestone in the management of these tumors in Italy. Oncological and surgical knowledge in the field of gastric cancer have changed dramatically over the last 25 years. The aim of this book is to offer an essential update on current diagnostic approaches and optimal treatment strategies. It gives comprehensive information on gastric cancer not neglecting the basic sciences, which can shed light on the carcinogenesis mechanisms involved in this pathology. The principles of tailored and multimodal treatment are examined according to the latest guidelines with the aim of providing a valuable synopsis for clinicians. The book not only reviews what has changed in the field of gastric cancer over the past quarter century but also offers the reader a glimpse of the future by describing the ongoing surgical and oncological trials which focus on new treatment frontiers such as immunotherapy and target therapy. It also seeks to incorporate the latest discoveries based on molecular classifications. Further, the book reflects the findings and experiences of Italian experts belonging to the GIRCG (Italian Research Group for Gastric Cancer) and will offer an excellent guide for oncological surgeons in their daily practice of caring for patients affected by gastric cancer.

Stomach cancer (also called gastric cancer) is the growth of cancer cells in the lining and wall of the stomach. Stomach cancer represents roughly 2 percent (25,500) cases of all new cancer cases yearly in the United States, but it is much more common in Japan, Great Britain, South America, and Iceland. It is associated with high salt in the diet, smoking, and low intake of fruits and vegetables.Infection with H. pylori is the main risk factor in about 80 percent or more of gastric cancers. It is more common in men. A very small percentage of diffuse-type gastric cancers are thought to be genetic. Hereditary Diffuse Gastric Cancer (HDGC) has only recently been identified and research is ongoing, but genetic testing and treatment options are available for families at risk. Metastasis occurs in 80-90 percent of individuals with stomach cancer, with a five year survival rate of 75 percent in those diagnosed in early stages and less than 30 percent of those diagnosed in late stages. This book presents new and important research from around the world.

Advances in Surgical Pathology: Gastric Cancer provides a concise, updated review of the pathological characteristics of gastric cancer, with an emphasis on exploring practical issues and recent developments. The book features current and emerging concepts in the field of gastric cancer, a disease whose management requires a multidisciplinary approach in which pathology plays a key role. Its six sections cover the essential histopathology of gastric cancer as well as related topics such as imaging evaluation, molecular diagnosis, and personalized treatment, among other areas of interest. Individual chapters written by international experts in the fields of pathology, gastrointestinal medical oncology, cancer epidemiology, and gastrointestinal radiology, address the fundamental issues surrounding gastric cancer, including its epidemiology, basic diagnostic features, differential diagnoses, pitfalls and complications, and treatments. Endoscopic evaluation and histology correlation are emphasized. The screening, clinical management, and treatment of gastric cancer are summarized in related book sections. Recent findings regarding the roles of immunohistochemistry and molecular testing in the diagnosis, prognosis, and personalized treatment of gastric cancer are also reviewed. The book also includes current knowledge regarding the molecular alteration of gastric cancer carcinogenesis and its impact on patient care.

Gastric cancer is still the most common cause of cancer death in the world, although in most countries, with the notable exception of the United States, its incidence is slowly declining. In statistical terms, gastric cancer is therefore the most formidable of cancer types, and its control is a pressing issue. Recent evidence indicates that the conversion of normal cells to so-called "clinical cancer" is the prerequisite for a multistage process which is intimately associated with an accumulation of multiple gene alterations including both oncogenes and tumor-suppressor genes. Gastric cancer is no exception, in that it reveals multiple gene changes whose scenario differs, depending on their occurrence in intestinal-type or diffuse-type gastric cancers. This book was planned for publication by the Japanese Research Society for Gastric Cancer in order to shed light on basic research and clinical practice in gastric cancer. The individual chapters, written by a variety of experts, contain numerous new topics related to all aspects of the disease, including epidemiology, experimental carcinogenesis, pathology, biology, diagnosis, and treatment. It is hoped that this book will be of use in basic research, pathological diagnosis, early detection, and therapy of gastric cancer. We would like to thank the staff of Springer-Verlag Tokyo for the excellent technical production.

This book presents important leading-edge research on stomach cancer. Stomach cancer (also called "gastric cancer") is the growth of cancer cells in the lining and wall of the stomach. Stomach cancer represents roughly 2% (25,500) cases of all new cancer cases yearly in the United States, but it is much more common in Japan, Great Britain, South America, and Iceland. It is associated with high salt in the diet, smoking, and low intake of fruits and vegetables. Infection with H. pylori is the main risk factor in about 80% or more of gastric cancers. It is more common in men. A very small percentage of diffuse-type gastric cancers are thought to be genetic. Hereditary Diffuse Gastric Cancer (HDGC) has only recently been identified and research is ongoing, but genetic testing and treatment options are available for families at risk. Metastasis occurs in 80-90% of individuals with stomach cancer, with a five year survival rate of 75% in those diagnosed in early stages and less than 30% of those diagnosed in late stages.

• Japan is a leader in screening for and treating gastric cancer - this title first publishes Japan’s newest research in English • Contributors are internationally recognized specialists with publications on gastrointestinal cancers in many high ranking medical journals from Europe and the USA • Michio Kaminishi was president of the 3rd International Conference of the ISGC

Gastric cancer is the second most common cause of cancer-related death in the world. There are no screening tests available for its diagnosis, therefore patients usually presents in late stages, associated with poor prognosis. Currently, many efforts are made toward new advances in the treatment strategies. The book makes an insight into the assessment of premalignant lesions, current management of early gastric cancer, risk and protective factors in gastric carcinogenesis. "Gastric cancer" provides a detailed description of the morphologic classification, molecular changes and epigenetic alterations of this tumor. The book describes the role of different diagnostic tools in the preoperative assessment of patients and the most important factors contributing to the prognosis. Moreover, it describes the current surgical and chemotherapeutic options for gastric neoplasm. This publication may open new and interesting gates for further research concerning carcinogenesis, genetic and epigenetic alterations, signaling pathways, H. pylori infection, the discovery of protective factors against gastric cancer and of revolutionary therapies of this tumor.